ERBB2 and metastatic neoplasm: IMPLICATIONS FOR PATIENT CARE: Integrating [89Zr]Zr-trastuzumab PET with DW-MRI offers a multiparametric imaging approach that may enhance lesion characterization and provide deeper biologic insight into HER2-positive metastatic disease.